このページの読み込み中にエラーが発生したようです.
当社チームに通知しましたが、問題が続くようでしたらEメールサポートウィジェットを使ってご連絡ください。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | No |
| Is net profit margin increasing? | No | No |
| Is asset turnover increasing? | No | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Keymed Biosciences Inc. |
| Abbisko Cayman Limited |
| JW (Cayman) Therapeutics Co. Ltd |
| CStone Pharmaceuticals |
| Staidson (Beijing) BioPharmaceuticals Co., Ltd. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| 2,162 | 2,256 | 2,126 | 2,616 | 300,204 | 6,998 | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -25% | 1% | -35% | -27% | -20% | -40% | ||
| Fiscal Year - 1 | -9% | -20% | -33% | -109% | -14% | -34% | ||
| Fiscal Year - 2 | -304% | NA | -23% | -92% | -9% | NA | ||
| Fiscal Year - 3 | NA | -253% | NA | -45% | -8% | -175% | ||
| Fiscal Year - 4 | NA | NA | 101% | NA | 1% | -100% | ||
| Fiscal Year - 5 | NA | 29% | 87% | -100% | 6% | -35% | ||
| Average | -113% | -61% | 20% | -75% | -7% | -77% | ||
| Median | -25% | -9% | -23% | -92% | -9% | -40% | ||
| Benchmarks | Ticker | |||||||
| Keymed Biosciences Inc. | SEHK:2162 | |||||||
| Abbisko Cayman Limited | SEHK:2256 | |||||||
| JW (Cayman) Therapeutics Co. Ltd | SEHK:2126 | |||||||
| CStone Pharmaceuticals | SEHK:2616 | |||||||
| Staidson (Beijing) BioPharmaceuticals Co., Ltd. | SZSE:300204 | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | Dec-05 | Mar-06 | Oct-05 | Feb-07 | Dec-21 | Feb-19 | ||
| Latest Fiscal Year | Dec-23 | Dec-24 | Dec-23 | Dec-23 | Dec-23 | Dec-23 | ||
| LTM Period | Jun-24 | Dec-24 | Jun-24 | Jun-24 | Sep-24 | Jun-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 82 | 504 | 173 | 457 | 351 | 14 | ||
| Fiscal Year | 354 | 504 | 174 | 464 | 364 | NA | ||
| Fiscal Year - 1 | 100 | 19 | 146 | 481 | 549 | 16 | ||
| Fiscal Year - 2 | 110 | NA | 31 | 244 | 584 | NA | ||
| Fiscal Year - 3 | NA | 23 | NA | 1,039 | 425 | 10 | ||
| Fiscal Year - 4 | NA | NA | 5 | NA | 661 | 13 | ||
| Fiscal Year - 5 | NA | 4 | 0 | 13 | 806 | 7 | ||
| Net Income | ||||||||
| Latest Twelve Months | (743) | 28 | (628) | (142) | (223) | (526) | ||
| Fiscal Year | (359) | 28 | (768) | (367) | (399) | (674) | ||
| Fiscal Year - 1 | (308) | (432) | (846) | (903) | (197) | (730) | ||
| Fiscal Year - 2 | (3,887) | (496) | (702) | (1,920) | (137) | (865) | ||
| Fiscal Year - 3 | (819) | (1,810) | (1,664) | (1,221) | (133) | (3,027) | ||
| Fiscal Year - 4 | (168) | (707) | (633) | (2,069) | 27 | (522) | ||
| Fiscal Year - 5 | NA | (134) | (273) | (470) | 134 | (288) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 4,068 | 2,115 | 2,652 | 1,660 | 1,487 | 1,834 | ||
| Latest Fiscal Quarter | 3,805 | 2,107 | 1,980 | 1,532 | 1,284 | 1,274 | ||
| Fiscal Year | 3,883 | 2,107 | 2,146 | 1,662 | 1,332 | 1,447 | ||
| Fiscal Year - 1 | 3,932 | 2,115 | 2,791 | 1,638 | 1,669 | 2,115 | ||
| Fiscal Year - 2 | 3,934 | 2,490 | 3,117 | 2,271 | 1,827 | 2,863 | ||
| Fiscal Year - 3 | 530 | 2,655 | 3,779 | 3,763 | 1,856 | 3,573 | ||
| Fiscal Year - 4 | 659 | 666 | 669 | 2,951 | 1,862 | 733 | ||
| Fiscal Year - 5 | NA | 320 | 341 | 1,632 | 2,772 | 988 | ||
| Fiscal Year - 6 | NA | NA | NA | 564 | 2,629 | NA | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 3,374 | 1,981 | 2,140 | 604 | 1,178 | 1,564 | ||
| Latest Fiscal Quarter | 2,637 | 1,958 | 1,482 | 468 | 1,033 | 1,062 | ||
| Fiscal Year | 2,986 | 1,958 | 1,684 | 457 | 1,021 | 1,189 | ||
| Fiscal Year - 1 | 3,340 | 1,981 | 2,354 | 449 | 1,354 | 1,802 | ||
| Fiscal Year - 2 | 3,651 | 2,346 | 2,791 | 1,207 | 1,551 | 2,490 | ||
| Fiscal Year - 3 | (1,095) | 2,536 | 3,430 | 2,954 | 1,588 | 3,234 | ||
| Fiscal Year - 4 | (276) | (1,105) | (942) | 2,482 | 1,635 | 219 | ||
| Fiscal Year - 5 | NA | (459) | (313) | 515 | 2,458 | 824 | ||
| Fiscal Year - 6 | NA | NA | NA | 426 | 2,209 | NA | ||